Sanofi pasteur Awarded Contract to Retrofit Influenza Vaccine Facility



    
    - Sanofi pasteur continues to join with the U.S. government in enhancing
    the nation's pandemic preparedness to protect public health -
    

    SWIFTWATER, Pa. and LYON, France, June 14 /CNW/ -- Sanofi pasteur, the
vaccines division of the sanofi-aventis Group, today announced it has been
awarded a $ 77.4 million contract by the United States Department of Health
and Human Services (HHS) to retrofit its existing influenza vaccine
manufacturing facility. Sanofi pasteur will contribute approximately $ 25
million to the overall project. The contract covers costs for design, retrofit
and the maintenance of the facilities at a state of readiness so the company
can switch to pandemic influenza vaccine manufacture at the HHS' request.
    The design phase will begin immediately. The retrofit will begin when the
company's new influenza vaccine manufacturing facility is licensed by the
United States Food and Drug Administration (FDA) and operational. The existing
facility will then be phased out and decommissioned for the retrofit.
    The existing facility has been modified over the years to produce
approximately 50 million doses of vaccine for the U.S. market during the
course of the past several influenza seasons.  When both facilities are
validated, the company's capacity will approximately triple from its current
capacity.
    This award marks the company's seventh pandemic influenza-related
contract with the U.S. government. Previous contracts have covered the
production of investigational doses for clinical trials; bulk vaccine for
stockpiling; the establishment and maintenance of laying chicken flocks to
enable year-round egg production (not just seasonal); as well as a contract to
speed the production process for new cell culture influenza vaccines,
including the design of a U.S.-based cell culture vaccine manufacturing
facility.

    
    Pandemic Influenza Overview
    
    Influenza is a disease caused by a highly infectious virus that spreads
easily from person to person, primarily when an infected individual coughs or
sneezes. An influenza pandemic is a global epidemic of an especially virulent
virus, newly infectious for humans, and for which there is no preexisting
immunity. This is why these pandemic strains have such potential to cause
severe morbidity and mortality. According to the World Health Organization
(WHO), the next pandemic is likely to result in 1 to 2.3 million
hospitalizations and 280,000 to 650,000 deaths in industrialized nations
alone. Its impact is expected to be even more devastating in developing
countries. In an attempt to minimize the impact of a pandemic, many countries
are developing national and transnational plans against an eventual influenza
pandemic situation.

    
    Sanofi Pasteur and Pandemic Preparedness
    
    Sanofi pasteur, the vaccines division of the sanofi-aventis Group, is
committed to global pandemic preparedness. As the world leader in research,
development and manufacturing of influenza vaccine, sanofi pasteur is actively
involved in projects in the U.S. and Europe, with the goal of developing a
vaccine to protect against a pandemic influenza virus.
    Sanofi pasteur is also investing in a major expansion of its influenza
vaccine production capacity in the U.S. and also of its vaccine production
capacity in France (Val de Reuil facility).

    
    For more information please visit
    www.sanofipasteur.com/pandemicpreparedness

    About sanofi-aventis
    
    Sanofi-aventis is one of the world leaders in the pharmaceutical
industry, ranking number one in Europe. Backed by a world-class R&D
organisation, sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases,
central nervous system, internal medicine and vaccines. Sanofi-aventis is
listed in Paris (EURONEXT: SAN) and in New York (NYSE:   SNY).
    Sanofi pasteur, the vaccines division of the sanofi-aventis Group,
provided more than a billion doses of vaccine in 2006, making it possible to
immunize more than 500 million people across the globe. A world leader in the
vaccine industry, sanofi pasteur offers the broadest range of vaccines
protecting against 20 infectious diseases. The Company's heritage, to create
vaccines that protect life, dates back more than a century. Sanofi pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR1 million in research and development. For more
information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

    
    Forward Looking Statements
    
    This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking
statements are statements that are not historical facts.  These statements
include financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future events, operations, products and services, and statements
regarding future performance.  Forward-looking statements are generally
identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans" and similar expressions.  Although sanofi-aventis'
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties,
many of which are difficult to predict and generally beyond the control of
sanofi-aventis, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the forward-
looking information and statements.  These risks and uncertainties include
those discussed or identified in the public filings with the SEC and the AMF
made by sanofi-aventis, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis'
annual report on Form 20-F for the year ended December 31, 2006.  Other than
as required by applicable law, sanofi-aventis does not undertake any
obligation to update or revise any forward-looking information or statements.

    
    sanofi pasteur                        sanofi pasteur
    Pascal Barollier                      Len Lavenda
    International Media Relations         U.S. Media Relations
    Tel: + 33-(0)4-37-37-51-41            Tel: +1-570-839-4446
    pascal.barollier@sanofipasteur.com    len.lavenda@sanofipasteur.com

    




For further information:

For further information: Pascal Barollier, International Media
Relations,  +33-4-37-37-51-41, pascal.barollier@sanofipasteur.com, or Len
Lavenda, U.S.  Media Relations, +1-570-839-4446,
len.lavenda@sanofipasteur.com, both of  sanofi pasteur Web Site:
http://www.sanofipasteur.com

Organization Profile

Sanofi Pasteur

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890